FDA warns of rare but irreversible risk of vision loss with Ozempic and analogs
In November 2026, the FDA warned that GLP-1 receptor agonists — semaglutide and tirzepatide — can rarely cause irreversible vision loss in one eye. We examine the mechanism, risk assessment, and popular myths.
Read more →